About this Research Topic
Cancer treatment has advanced significantly in recent years, yet drug resistance remains a major obstacle, particularly in aggressive cancer types. Drug-resistant cancer cells often undergo metabolic reprogramming, allowing them to survive therapeutic interventions that would otherwise be lethal. This metabolic flexibility enables cancer cells to adapt to harsh conditions and evade drug effects, resulting in tumor progression despite treatment.
Emerging research in pharmacology suggests that targeting these metabolic adaptations can effectively inhibit resistant cancer cell populations. Multi-omics approaches-encompassing genomics, transcriptomics, proteomics, and metabolomics-offer a comprehensive view of these complex cellular changes. By integrating data from multiple biological layers, researchers can better understand how metabolic pathways are altered in drug-resistant cancers and identify potential pharmacological targets. This research topic aims to explore these pathways to develop targeted therapies that disrupt the metabolic resilience of drug-resistant cancer cells, improving patient outcomes.
The primary goal of this research topic is to address the challenge of drug resistance in cancer, a significant barrier to effective treatment and a leading cause of cancer-related mortality. Drug-resistant cancer cells often evade traditional therapies through metabolic reprogramming, altering energy production and resource utilization pathways to survive and thrive under pharmacological stress. Despite advancements, there is limited understanding of how these metabolic shifts specifically contribute to resistance mechanisms, and, more importantly, how they can be effectively targeted.
The scope of this Research Topic centers on understanding and targeting metabolic adaptations in drug-resistant cancer through multi-omics and pharmacological approaches. We invite original research, reviews, and methodology papers focusing on specific themes, including but not limited to:
1: Mechanisms of Metabolic Reprogramming: Studies that explore metabolic changes in drug-resistant cancer cells, including glycolysis, lipid metabolism, and oxidative phosphorylation.
2: Multi-Omics Integration: Research utilizing multi-omics platforms to identify key biomarkers or pathways linked to cancer metabolism and resistance.
3: Pharmacological Targeting of Metabolic Pathways: Investigations into compounds or interventions targeting metabolism to restore drug sensitivity.
4: Clinical Implications and Biomarker Development: Studies aiming to translate findings into clinical biomarkers or therapeutic targets.
We also welcome contributions in the form of experimental studies, systematic reviews, meta-analyses, and translational research that offer insights into metabolism-based therapeutic strategies for drug-resistant cancer.
Please note: If patient data are analyzed, a comprehensive description of the patients including sex, age, diagnostic criteria, inclusion and exclusion criteria, disease stage, therapy received, comorbidities as well as additional clinical information and assessment of clinical response/effects should be included. If genetic, proteomics, metabolomics, or other omics data are analyzed, a comprehensive description of the methods and the rationale for selecting the specific data studied should be provided. Studies related to natural compounds, herbal extracts, or traditional medicine products, are outside the scope of this Research Topic and should instead be submitted to the specialty section of Ethnopharmacology. Studies solely based on the analysis of public databases or published evidence, with no further experimental insights or insufficient experimental validation, will not be included in this Research Topic.
Emerging research in pharmacology suggests that targeting these metabolic adaptations can effectively inhibit resistant cancer cell populations. Multi-omics approaches-encompassing genomics, transcriptomics, proteomics, and metabolomics-offer a comprehensive view of these complex cellular changes. By integrating data from multiple biological layers, researchers can better understand how metabolic pathways are altered in drug-resistant cancers and identify potential pharmacological targets. This research topic aims to explore these pathways to develop targeted therapies that disrupt the metabolic resilience of drug-resistant cancer cells, improving patient outcomes.
The primary goal of this research topic is to address the challenge of drug resistance in cancer, a significant barrier to effective treatment and a leading cause of cancer-related mortality. Drug-resistant cancer cells often evade traditional therapies through metabolic reprogramming, altering energy production and resource utilization pathways to survive and thrive under pharmacological stress. Despite advancements, there is limited understanding of how these metabolic shifts specifically contribute to resistance mechanisms, and, more importantly, how they can be effectively targeted.
The scope of this Research Topic centers on understanding and targeting metabolic adaptations in drug-resistant cancer through multi-omics and pharmacological approaches. We invite original research, reviews, and methodology papers focusing on specific themes, including but not limited to:
1: Mechanisms of Metabolic Reprogramming: Studies that explore metabolic changes in drug-resistant cancer cells, including glycolysis, lipid metabolism, and oxidative phosphorylation.
2: Multi-Omics Integration: Research utilizing multi-omics platforms to identify key biomarkers or pathways linked to cancer metabolism and resistance.
3: Pharmacological Targeting of Metabolic Pathways: Investigations into compounds or interventions targeting metabolism to restore drug sensitivity.
4: Clinical Implications and Biomarker Development: Studies aiming to translate findings into clinical biomarkers or therapeutic targets.
We also welcome contributions in the form of experimental studies, systematic reviews, meta-analyses, and translational research that offer insights into metabolism-based therapeutic strategies for drug-resistant cancer.
Please note: If patient data are analyzed, a comprehensive description of the patients including sex, age, diagnostic criteria, inclusion and exclusion criteria, disease stage, therapy received, comorbidities as well as additional clinical information and assessment of clinical response/effects should be included. If genetic, proteomics, metabolomics, or other omics data are analyzed, a comprehensive description of the methods and the rationale for selecting the specific data studied should be provided. Studies related to natural compounds, herbal extracts, or traditional medicine products, are outside the scope of this Research Topic and should instead be submitted to the specialty section of Ethnopharmacology. Studies solely based on the analysis of public databases or published evidence, with no further experimental insights or insufficient experimental validation, will not be included in this Research Topic.
Keywords: cancer therapy, pharmacological therapy, cancer metabolism, multi-omics, drug-resistant EMT, metastasis
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
